Immune responses to SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO Study

Accepted/In Press date: 10 March 2022

e-pub ahead of print date: 24 March 2022

Published date: 24 March 2022

Additional Information: Funding Information: S.H.L., N.C., M.J., D.J.P., A.O., H.C., C.M., A.K., A.R.C., A.H.T., K.L., D.J., B.W., T.W., A.T.B., K.R., B.S., C.G., D.A., J.F., O.B., J.B., V.M., A.B.A.-N., L.R., T.M., P.W.M.J. and D.G. declare no competing interests. C.F. receives consultancy fees from AstraZeneca and participates in an advisory board for AstraZeneca. M.A. receives research funding from Pfizer. G.P.C. receives research funding from Pfizer and participates in advisory boards for AstraZeneca and Pfizer. R.L. reports receiving speaker fees and honoraria from Janssen. A.J.D. reports receiving research funding and honoraria from AstraZeneca and Janssen. S.N.F. participates in advisory boards related to vaccines or grants for contract commercial clinical trials that were paid to S.N.F.’s institution (with no personal payment of any kind) from AstraZeneca/Medimmune, Sanofi, Pfizer, Seqirus, Merck, GSK, J&J, Merck and Valneva, outside the submitted work. Funding Information: The PROSECO study is funded by the Blood Cancer UK Vaccine Research Collaborative, which is led by Blood Cancer UK in partnership with Myeloma UK, Anthony Nolan and the British Society for Haematology (21009) to S.H.L. and supported by Cancer Research UK Advanced Clinician Scientist Fellowship to S.H.L. (A27179), the Cancer Research UK/National Institute for Health Research (NIHR) Southampton Experimental Cancer Medicine Center to A.J.D. (A25141), the NIHR Southampton Clinical Research Facility (Southampton Research Biorepository) and NIHR Southampton Biomedical Research Center. D.G. receives support from the NIHR Great Ormond Street Biomedical Research Center. G.P.C. acknowledges support from the NIHR Oxford Biomedical Research Center and CRUK Experimental Cancer Medicines Center. We thank members of the Blood Cancer UK Vaccine Task Force for their advice. We thank J. Wilbur at Meso Scale Discovery for technical support and provision of laboratory reagents. We sincerely thank all the participating sites’ research staff for their hard work and we also thank the research participants. Publisher Copyright: © 2022, The Author(s). Copyright: Copyright 2022 Elsevier B.V., All rights reserved.

Local EPrints ID: 456562

URI: http://eprints.soton.ac.uk/id/eprint/456562

DOI: doi:10.1101/2021.12.08.21266760

ISSN: 2662-1347

PURE UUID: fe7e9f0f-6bb5-4e9b-9348-db909e038e0f

ORCID for Beth Stuart: orcid.org/0000-0001-5432-7437

ORCID for James Batchelor: orcid.org/0000-0002-5307-552X

ORCID for Saul N Faust: orcid.org/0000-0003-3410-7642

ORCID for Peter W M Johnson: orcid.org/0000-0003-2306-4974

ORCID for Andrew J Davies: orcid.org/0000-0002-7517-6938

Date deposited: 05 May 2022 16:33

Last modified: 17 Mar 2024 03:14